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Background: Mycosis fungoides (MF) is a rare skin condition, effectively treated by irradia-
tion.  Since 1951, different methods of total skin irradiation have been developed. Although
dose–response effect has been demonstrated in many publications, controversies about low
dose treatment still exist.
Aim: The analysis of results of the total skin electron irradiation (TSEI), especially low dose
TSEI in comparison with standard dose treatment is the subject of this review. Also, acute
and late side effects of radiotherapy in MF are discussed.
Materials and methods: Medline search and analysis of studies published between 1995 and
2012,  containing key words: mycosis fungoides, standard dose TSEI, low dose TSEI, total skin
electron beam therapy (TSEBT).
Results: Detailed analysis of relevant studies demonstrated that standard dose radiotherapy
30–36 Gy is the most effective treatment used in clinical practice. Objective response rate
(ORR) is high, especially for less advanced stages of disease. Complete response rate (CR),
although slightly lower, is still relatively high.
For more advanced MF, TSEI serves as a very good method of palliative treatment and
relief of symptoms, like pruritus, pain or desquamation.
There is no consensus regarding low dose TSEI; the method is widely accepted as a pal-
liative treatment or in case of reirradiation.
Conclusions: Standard dose TSEI is an effective method of MF treatment for radical and pal-liative treatment, producing high rate of ORR and reasonably long time to progression (TTP).
Acute and late side effect of treatment are mostly mild and easy to manage. Low dose TSEI
is  still in the phase of clinical studies.
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1.  Background
Mycosis fungoides (MF) is a relatively rare disease. The etiol-
ogy and natural course of the disease have been discussed in
separate publications. Despite its indolent course, even at low
stages of disease, patients report unpleasant symptoms: pru-
ritus and desquamation, patches and plaques and, at more
advanced stages, erythrodermia mycosis fungoides is a dis-
ease which is not easy to treat and according to the majority of
sources permanent recovery is unlikely. It is possible to obtain
periods of remission of different duration as well as to alleviate
or even eliminate the symptoms. The patient’s age, the stage
of the disease with or without lymph nodes being affected,
and the presence of the site of the disease other than the skin
are among the prognostic factors of the disease progression.1
Affected lymph nodes are predictors of the MF progression but
do not reduce the long-term survival.2 In the treatment, top-
ical methods are used, especially at the lower stages of the
disease. The method of therapy which is regarded as the most
effective is total skin electron irradiation (TSEI). The present
review will focus on clinical results of irradiation at different
clinical stages with consideration of the total administered
dose.
Irradiation of patients with MF  has been in use since
1951. Total skin electron irradiation (TSEI) or total skin elec-
tron beam therapy (TSEBT) is not only an effective treatment
method at early stages of the disease, but it also gives effects
in palliative treatment when the disease is advanced.3,4
In daily clinical practice, a number of irradiation methods
– whose detailed characteristics are presented elsewhere –
are employed. The most common methods are the Stanford
method5 and the rotational method.6
The choice of treatment and its results depend to a large
degree on the stage of the disease, categorized according to the
classiﬁcation: T-tumor N-node M-metastasis B-blood. On the
basis of this system, in 2007 the classiﬁcation of the European
Organization of Research and Treatment of Cancer EORTC and
International Society for Cutaneous Lymphomas was created,
included also in the American Joint Committee on Cancer
(AJCC).7–9
Electron irradiation of the skin is recommended as ini-
tial treatment mainly for patients with thickened plaques.4
This method is more  effective than topical therapies, like
nitrogen mustard or phototherapy, in the case of thickened
lesions as radiation penetrates thicker inﬁltrations much bet-
ter than medication used topically.11 However, also in the case
of patients with the disease at much more  advanced stage, this
method is commonly accepted for palliative treatment.4
The remission of lesions and the reduction of symptoms
occur both during the therapy and thereafter, some time fol-
lowing the completion of therapy. Monitoring patients with MF
once they have completed radiotherapy is necessary in order
to evaluate properly the response to treatment.
Irradiating the total area of skin even by means of non-
penetrating radiation which stops at the dermis still causes
some side effects. Although in the majority of cases these side
effects are not severe, they commonly include soreness and
redness of the skin, desquamation, the separation of ﬁnger-
nails from their nail bed (onycholysis) or hair loss.11diotherapy 1 9 ( 2 0 1 4 ) 99–103
Taking into consideration the dose received by the skin,
which for the conventional TSEI is 30–36 Gy,5 repeated course
of TSEI is very rarely used for fear of intensiﬁed late radiation
effects such as skin necrosis and bone marrow suppression.12
Therefore, in some medical centers the possibility of irradiat-
ing the total area of the skin with doses lower than 30 Gy is
being tested although early studies concerning MF  radiothe-
rapy indicate a strong dose–response effect.5 The aim of this
review was to analyze available publication regarding low dose
TSEBT in terms of feasibility of this method in clinical practice.
To adequately assess feasibility of low dose TSEBT, results of
this approach were discussed together with standard dose
TSEBT, in terms of both: outcome and side effects. Moreover,
special clinical indications for low dose TSEBT were presented.
2.  Method
In order to review treatment results in the published studies an
analysis of literature was undertaken using PubMed. Medline
browsers.
The key words used were the following: mycosis fungoides,
total skin electron irradiation (TSEI), total skin electron beam
therapy (TSEBT), low dose TSEBT, mycosis fungoides reirradi-
ation.
Due to the indolent course of the disease with relatively
long median survival, studies from the years 1995–2012 were
included in the review. Both retrospective and prospective
studies which were published in English and which evalu-
ated among their end-points the objective response (OR) and
the rate of complete response (CR) were taken into account.
Since MF is a relatively rare disease, studies on small num-
bers of patients were not disqualiﬁed. Duplicate studies which
discussed the results of the same groups of patients were
excluded from the review. The references of the studies incor-
porated in the review were analyzed and relevant further
studies were subsequently added.
3.  Results
Medline search identiﬁed 158 publications describing TSEI in
the treatment of MF. 11 studies were eligible for analysis of
treatment results, presenting analysis of long-term follow-up.
3.1.  Standard  dose  TSEI
Table 1 presents the results of studies which resorted to TSEI
using various dose. Generally, the doses amounted to 30–36 Gy.
Most studies report very good results of the treatment of initial
stages of MF, the response rate is 70–100% for all the stages,
whereas for T1-2 N0 it reaches 97–100%. Together with the
progression of the disease and the occurrence of extracuta-
neous lesions, the response rate drops, complete remission
is achieved for a smaller group of patients and it lasts for a
shorter time. 10-year disease-free survival rate is 50% for the
IA stage, it drops to 20–10% for the IB stage,18,21 and below 10%
for the IIB stage. The results of irradiation for patients with
stage III disease differ depending on blood involvement. In the
case of patients with erythrodermia, the rate of remission is
75%, but 5-year progression free survival (PFS) is only 25%. For
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Table 1 – Results of treatment of MF  with TSEI, standard (high) dose and low dose.
Study/years
conducted
No. of Pts
(sex: M/W)
Stage TNM
(patients)
Median age
(range)
TSEI
Dose – Gy
(patients)
FU median
(months)
ORR% CR % (stage
TNM)
OS% (years) TTP
(months)
Navi D
Stanford, 1970–200713
180 T2 (103)
T3 (77)
NA 30–40 77 100 60 all
75 (T2)
47 (T3)
59 (5)
40 (10)
NA
Maignon
Dijon, 1975–199514
45 (34/11) T3, T4 61  (27–87) 24–30 [pho-
ton/electron]
85  (18–244) 75
81-T3
1-T4
79-N1
70-N3
24  all
67 (T3)
28 (T4)
64 (N1)
41 (N3)
(5y OS)
37 [T3]
44 [T4]
63 [N1]
32 [N3]
NA
Kamstrp MR
Copenhagen,
2002–200615
10 (6/4) T2 (7)
T3 (3)
N1 (1)
N0 (9)
68.7 (55–82) 4 NA 80 2 NA 2.7
Lindahl LM
Aarhus, 2001–200810
35 T1 (2)
T2 (14)
T3 (17)
T4 (2)
66  (41–85) 30 (25)
4 (10)
7.6 [3d-3,7y] 100 68 [HD]
10 [LD]
66.7 (T2)
78.6 (T3)
NA  4
Shouman T
Cairo, 1997–200216
40 T1, T2 (34) T3
(6)
50 (24–63) 35 19.5 (6–48) 100 87.5 NA 10.5
Funk A
Heidelberg,
1993–20044
18 (15/3) IIB (1)
IVA (10)
IVB (7)
59  (34–78) >25 (12)
<25 (6)
11  89 50 NA NA
Kamstrup MR
Copenhagen
Aarhus, 2009–201017
10 (8/2) T2 (6)
T3 (2)
T4 (2)
62  (48–84) 10 NA 90 70 NA 4.2
Harrison
C Stanford,
1958–19957
102 (68/34) T2 (51)
T3 (29)
T4 (22)
59  (21–90) 5–<10
10–<20
20–<30
NA  96 16 [<10 Gy]
35 [<20 Gy]
34 [<30 Gy]
NA  NA
Jones GJ
Ontario, 1977–199218
146 T1 (44%)
T2 (34%)
55  30 (25)
35 (121)
60 82 NA 100 (10) [for
35 Gy]
NA
Quiros PA
Yale, 1974–199319
114 T1 (39)
T2 (75)
58  (20–88) 36 62 (3–179) NA 97 (T1)
87 (T2)
(5y OS): 85
[all]
100 [PUVA+]
82 [PUVA-]
NA
Ysebaert L
Dijon, 1975–200120
141 T1 (24)
T2 (33)
61  (19–84) 30 114 (14–300) 97.4 87.5 (T1)
84.8 (T2)
90  (5)
65 (10)
NA
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two-thirds of the group of patients with the B0 feature disease-
free survival is 10 years,18 in contrast to patients with the B1
feature whose survival is only 15%. Patients with identiﬁed
stages IVA and IVB can undergo effective palliative treatment,
the complete remission rate is 70% and in some cases long-
term remissions are obtained. Post-treatment survival for IV
B stage rarely reaches 5 years. However, TSEI improves the
quality of life and reduces the unpleasant symptoms.18
3.2.  Low  dose  TSEBT
Published results of research on low-dose TSEI are scarce,
which impedes drawing deﬁnite conclusions concerning the
outcomes of low-dose therapy. The study conducted in the
Department of Dermatology in Copenhagen showed that
doses as low as 4 Gy delivered in 4 fractions administered to
the skin in the process of total skin irradiation may induce par-
tial remission in the case of early stage mycosis fungoides MF
– IB-II; however, it is a short-term remission.10,15 Despite dis-
couraging results of low-dose irradiation with doses of 4 Gy,
attempts have been made to use this method and irradiate
the skin using the dose of 10 Gy.17 Kamstrup obtained satis-
factory results of both clinical response and remission time,
particularly in patients with complete remission.
3.3.  Palliative  treatment
TSEI is also applied in strictly palliative treatment: in the MF
resistant to psoralen ultra violet A and chemotherapy at stage
IIB–IV. In his research, Funk presented encouraging results of
TSEI irradiation with the dose of >29 Gy: in 50% of patients
a complete remission was noted which continued for 1–18
months. The actuarial one-year progression free survival was
24%.4 89% of patients experienced the reduction of symptoms
such as itch, pain, bleeding or ulcers, which, however, was
accompanied by the occurrence of temporary side effects of
the treatment.
3.4.  Side  effects
An acute radiation – induced reaction mainly includes drying
and desquamation of the skin, erythema, edema, particularly
on the limbs, overpigmentation and hair loss. Existing skin
ulcers due to inﬁltration of the skin might lead to temporary
epitheliolysis or bacterial superinfection.4
These symptoms are nearly always temporary and mostly
subside after ca. 2–3 weeks.14 Acute reaction is intensiﬁed
around the second week of the treatment. Moreover, leucony-
chia and dystrophy occur during the stage of acute reaction
and persist for a longer period.22 Due to the presence of the
symptoms and need for supportive care, patients treated with
TSEI are hospitalized.
General symptoms which occur in a number of patients
especially in the case of more  advanced stages are myelo-
suppression and fatigue. Late radiotherapy-induced reactions
such as hyper- and depigmentation as well as hyperkeratosis
occur a few years after treatment completion. Another fre-
quently observed symptom is hipohydrosis caused by sweat
gland atrophy.4diotherapy 1 9 ( 2 0 1 4 ) 99–103
Some authors report the occurrence of rare symptoms such
as benign secondary neoplasms, i.e. diffuse lipoma or eccrine
poroma.23
4.  Discussion
TSEI is one of more  efﬁcient, widely accepted methods of
treating MF which is also recommended by EORTC guidelines.
Although, as numerous authors emphasize, TSEI is not a rad-
ical treatment for MF, the rate and long period of obtained
complete remissions of MF at less advanced stages as well as
a satisfactory palliative effect in the case of the advanced dis-
ease, make radiotherapy the basic method of MF treatment.
The results of treatment presented in available publications
are consistent for both more  and less advanced stages. Like-
wise, prognostic factors such as age, stage or involvement of
lymph nodes do not raise controversy.
Discrepancies in outcomes of treating T2 and T3 stages,
which can be found in literature stem, according to various
authors, derive from the difﬁculty in deﬁning these MF stages
histopathologically and clinically. Authors indicate that sim-
ilar problems occur in the case of assessing lymph nodes
involvement which may cause differences in the evaluation
of treatment results.
The focus of the current studies is on prolonging remis-
sion and reducing the recurrence rate particularly at stage IB.
The proposed strategies are chieﬂy targeted at an adjuvant
and concurrent therapy including PUVA19 administration of
topical drugs such as bexarotene or systemic treatment like
metothrexate, gemcytabine or liposomal doxorubicin. Admin-
istering mechloretamine (nitrogen mustard) concomitantly
with TSEI was not satisfactory both in terms of complete
remission rate and overall survival.3
It was demonstrated that without adjuvant therapies for
stage IB, 10-year-cause-speciﬁc survival is 96%, and median
overall survival is 15–20 years, and half of deaths are caused
by MF.18 Since adjuvant treatment with high-dose cytostatic
drugs and bone marrow transplant has not provided to deliver
the expected satisfactory results, administering cytostatics
and delivering TSEI at the same time has been proposed21 as
well as including total nodal irradiation.24
Historic papers on radiotherapy of MF show dose levels
evolved and increased from low doses of 8 Gy to higher doses
of 30–36 Gy, which was the result of ﬁnding a dose-response
relation. This was the reason for abandoning treatment with
low doses of 4–10 Gy, which as several publications conﬁrm,
have not proved to be sufﬁciently effective. However, recently,
the return to low-dose TSEI in MF and attempts at ﬁnding
application for this kind of radiotherapy have been observed.
Treatment results are inconsistent: some papers present a
favorable toxicity proﬁle and emphasize a similar complete
remission rate with the use of low doses.15
An undeniable advantage of such a treatment scheme is the
fact that it may be repeated without fearing severe radiation-
induced reactions, both early and late, while the length of
remission is the main disadvantage of low-dose techniques.
The group of patients treated with low-dose TSEI is still small,
which does not allow to draw a valid conclusion. Some authors
propose introducing low-dose TSEI schemes in the case of
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lymphoma. Hematol Oncol Clin North Am 2003;17(6):1485–90.reports of practical oncology and
requent MF  recurrences, which makes it possible to repeat
adiotherapy.7 Lower total doses in these cases allow repeated
otal skin electron therapy without severe late symptoms,
uch as skin necrosis or chronic, refractory radiodermatitis.
n the basis of available publications, it appears that total skin
lectron beam therapy will be applicable in the case of care-
ully selected group of patients receiving primary treatment or
uffering from recurrence as well as those receiving palliative
reatment.25 In the future, low-dose TSEI may be applied in a
oncomitant therapy with radiosensitizers such as cytostatics
r targeted therapy.
The assessment of treatment results, beside standard end-
oints such as complete remission or disease-free survival,
hould also take into account the quality of life of the patient
eceiving treatment26,27 and be regarded as one of the most
mportant end-points of the study, especially in case of disease
hich has a relatively long natural history and troublesome
ymptoms such as itch and desquamation.
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